论文部分内容阅读
目的:探讨联合应用索他洛尔和甲巯咪唑治疗甲状腺机能亢进性心房颤动的临床疗效和安全性,旨在为规范甲状腺机能亢进性心房颤动的治疗方案提供参考依据。方法:随机选取我院2011年1月～2011年12月收治的86例甲状腺机能亢进性心房颤动患者为研究对象并联合应用索他洛尔和甲巯咪唑对其进行治疗;治疗期间,观察此86例患者的不良反应发生情况;治疗2个月后,比较此86例患者治疗前后的T3T4水平和HR变化情况。结果:①在此86例患者中,治疗显效和治疗有效的患者共有76例,治疗的总有效率为88.37%。②此86例患者的T3水平由治疗前的19.68±3.27nmol/L降为治疗后的10.12±2.89nmol/L,治疗前后的T3水平差异具有显著性(P<0.05);T4水平由治疗前的285.78±54.64nmol/L降为治疗后的166.37±38.51nmol/L,治疗前后的T4水平差异具有显著性(P<0.05);HR水平由治疗前的92.78±22.18次/min降为治疗后的70.26±19.58次/min,治疗前后的HR水平差异具有有显著性(P<0.05)。③在治疗期间,此86例患者均未见明显的药物不良反应。结论:联合应用索他洛尔和甲巯咪唑治疗甲状腺机能亢进性心房颤动具有疗效确切、安全可靠等优点,是一种值得在临床上推广和应用的治疗甲状腺机能亢进性心房颤动的用药法。
Objective: To investigate the clinical efficacy and safety of combination of sotalol and methimazole in the treatment of hyperthyroidism with atrial fibrillation, and to provide a reference for regulating the treatment of hyperthyroidism with atrial fibrillation. Methods: A total of 86 patients with hyperthyroidism with atrial fibrillation admitted in our hospital from January 2011 to December 2011 were selected as the study subjects and treated with sotalol and methimazole. During the treatment, 86 patients with adverse reactions occurred; after 2 months of treatment, the 86 patients before and after treatment T3T4 levels and changes in HR. Results: Among the 86 patients, there were 76 patients with effective and effective treatment, and the total effective rate was 88.37%. (2) The T3 level of the 86 patients decreased from 19.68 ± 3.27nmol / L before treatment to 10.12 ± 2.89nmol / L after treatment, and there was a significant difference in T3 levels before and after treatment (P <0.05) (285.78 ± 54.64nmol / L) after treatment was 166.37 ± 38.51nmol / L after treatment, the difference of T4 level before and after treatment was significant (P <0.05); HR decreased from 92.78 ± 22.18 times / min before treatment to 70.26 ± 19.58 times / min, there was significant difference in HR before and after treatment (P <0.05). ③ During the treatment, no obvious adverse drug reaction was found in these 86 patients. Conclusion: The combination of sotalol and methimazole for the treatment of hyperthyroidism with atrial fibrillation has the advantages of being effective, safe and reliable, which is worthy of clinical promotion and application in the treatment of hyperthyroidism atrial fibrillation.